Duplication of Coagulation Factor Genes and Evolution of Snake Venom Prothrombin Activators by Shiyang Kwong & R. Manjunatha Kini
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
14 
Duplication of Coagulation Factor 
Genes and Evolution of Snake 
Venom Prothrombin Activators 
Shiyang Kwong1 and R. Manjunatha Kini1,2 
1Department of Biological Sciences, Faculty of Science 
National University of Singapore, Singapore  
2Department of Biochemistry, Medical College of Virginia 
Virginia Commonwealth University, Richmond,Virginia  
1Singapore  
2USA 
1. Introduction  
Snake venom is a complex mixture of pharmacologically active molecules which are 
responsible for immobilization, paralysis, death and digestion of prey organisms. This 
armory of toxins has evolved to target two key systems, namely the neuromuscular and 
circulatory systems, in order to induce rapid immobilization and death. So far, several 
hundreds of protein toxins from snake venoms have been purified and characterized. Most 
of these toxins have been documented to be structurally, and at times functionally, similar to 
proteins expressed in different tissues of the body. For example, elapid phospholipase A2 
toxins are structurally and catalytically similar to mammalian pancreatic phospholipase A2 
enzymes (Robin Doley et al. 2009). Similarly, sarafotoxins are structurally and functionally 
similar to endothelins produced primarily in endothelium (Landan et al. 1991a).  Based on 
such structural and functional similarities, it is hypothesized that toxin proteins are 
“recruited” from body proteins by gene duplication (Fry 2005). Accordingly, the genes of 
body proteins are duplicated and modified to have differential and specific expression in 
venom glands. This phenomenon is broadly termed as “recruitment”. This “recruitment” 
process of body proteins has not only been observed in snakes but also in various other 
venomous animals, such as cone snails, spiders, scorpions and sea anemones as well as 
hematophagous animals (Fry et al. 2009). Although this overarching concept existed in the 
field of snake venom toxins for decades, there is not much direct molecular evidence for this 
process of “recruitment”.   
Our laboratory has extensively characterized prothrombin activators from Australian elapid 
snake venoms and documented their structural and functional similarity with mammalian 
plasma coagulation factors. Through systematic, detailed studies, we provided the 
molecular details of the “recruitment” of venom prothrombin activators from plasma 
coagulation factors after gene duplication. We also identified several key structural changes 
that make these prothrombin activators better toxins. In this chapter, we will describe the 
first molecular evidence for the “recruitment” process and the evolution of prothrombin 
activators in venoms of Australian elapid snakes.  
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2. Snake venom prothrombin activators  
As mentioned above, the circulatory system is one of the main targets of snake venom 
toxins.  These toxins affect heart function (e.g., cardiotoxins), vasculature and blood pressure 
(e.g., sarafotoxins, natriuretic peptides and hemorrhagic toxins), blood coagulation (e.g., 
procoagulant and anticoagulant proteins), platelet aggregation (e.g., agonists and 
antagonists) and fibrinolysis (e.g., direct and indirect fibrinolytic proteinases) (Braud et al. 
2000; Chow and Kini 2001; Hutton and Warrell 1993; Kini 2004; Kini and Chow 2001; Kini 
and Evans 1990; Markland 1997; Markland 1998; Morita 2004). All procoagulant proteins are 
generally proteinases that promote blood coagulation by activating zymogens of specific 
plasma coagulation factors (Davie 2003). Prothrombin activators are a group of 
procoagulant proteins that specifically activate prothrombin to thrombin, which then 
induces blood coagulation through fibrin clot formation.  
Several prothrombin activators have been identified and characterized from snake venoms 
(Gao et al. 2002; Hasson et al. 2003; Joseph and Kini 2001; Kornalik and Blomback 1975; 
Morita and Iwanaga 1978; Rosing and Tans 1991; Rosing and Tans 1992; Schieck et al. 1972; 
Silva et al. 2003; Speijer et al. 1986; St Pierre et al. 2005; Yamada and Morita 1997), and based 
on their properties (structure, cofactor requirements and end-products formed), these snake 
venom prothrombin activators have been classified into four groups (Kini et al. 2001) (Table 
1). Group A and B prothrombin activators, such as ecarin from Echis carinatus venom 
(Kornalik and Blomback 1975; Morita and Iwanaga 1978; Nishida et al. 1995; Schieck et al. 
1972) and multactivase from E. multisquamatus venom (Yamada and Morita 1997), are 
metalloproteinases which induce coagulation by converting prothrombin to meizothrombin. 
These proteins are structurally distinct from blood coagulation factors. Group C and D 
prothrombin activators, such as oscutarin from Oxyranus scutellatus venom (Owen and 
Jackson 1973; Speijer et al. 1986; Walker et al. 1980; Welton and Burnell 2005) and notecarin 
from Notechis scutatus scutatus venom (Tans et al. 1985), are serine proteinases that induce 
coagulation by converting prothrombin to thrombin. These proteins exhibit functional 
similarity to mammalian plasma coagulation factors. However, no detailed structural 
information of these proteins was available. To fill this void, we initiated structural studies 
of these prothrombin activators. We characterized one representative each of group C 
(pseutarin C) and group D (trocarin D) prothrombin activators. Our results show that snake 
venom prothrombin activators are structurally and functionally similar to mammalian 
plasma coagulation factors.  
 
Group 
Cofactor 
Requirements
Type of 
proteinase 
Product 
formed 
Estimated Size
Similar to Plasma 
Coagulation 
Factors 
Examples 
A None 
Metalloproteinase Meizothrombin
~47 kDa 
None 
Ecarin 
B Ca2+ 
Two subunits of 
~25 and ~60 kDa
Carinactivase, 
multactivase 
C 
Ca2+ plus 
phospholipids
Serine proteinase Thrombin 
Two subunits of 
~60 and ~220 
kDa 
“FXa-FVa” 
complex 
Pseutarin C 
oscutarin,  
D 
Ca2+ plus 
phospholipids 
plus factor Va
~60 kDa FXa 
Trocarin D, 
hopsarin D, 
notanarin D 
Table 1. Classification of snake venom prothrombin activators 
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2.1 Group D prothrombin activators  
Group D prothrombin activators are found exclusively in the venom of Australian elapid 
snakes (Rosing and Tans 1991). Notecarin from Notechis scutatus scutatus venom was the first 
member of this group to be isolated and characterized (Tans et al. 1985). Since then, similar 
prothrombin activators have been characterized from several other snake venoms.  They are 
glycoproteins with a molecular weight of ~50 kDa (Table 1). As a group of proteins, they 
share striking resemblances and requirements for optimal activity with activated 
mammalian plasma coagulation factor X (FXa) (Table 1) (Joseph et al. 1999; Marsh et al. 
1997; Rao and Kini 2002; Stocker et al. 1994; Tans et al. 1985).  
Venom of the Australian elapid Tropidechis carinatus (rough-scaled snake) was documented 
to have procoagulant properties 29 years ago (Chester and Crawford 1982). A prothrombin 
activator was isolated using gel filtration and benzamidine-based affinity chromatography 
and was partially characterized (Marsh et al. 1997). Our laboratory purified a prothrombin 
activator, trocarin D, from T. carinatus venom to homogeneity using a series of high 
performance liquid chromatography techniques including gel filtration, ion-exchange and 
reverse-phase chromatographies (Joseph et al. 1999). This purification procedure was 
refined to a single-step reverse-phase chromatographic method and was subsequently used 
for the purification of several other group D prothrombin activators such as notanarin D 
from N. ater niger venom, notecarin D from N. scutatus venom and hopsarin D from 
Hoplocephalus stephensi venom (Rao et al. 2003a). Our laboratory characterized trocarin D for 
its functional and structural properties in detail as a representative of group D prothrombin 
activators. 
Functionally, trocarin D has properties which are similar to mammalian plasma coagulation 
FXa. They both promote blood coagulation by activating prothrombin to thrombin (Joseph 
et al. 1999). Trocarin D and FXa achieve activation of prothrombin by cleaving the same 
peptide bonds (Arg274-Thr275 and Arg323-Ile324). Both proteins have identical co-factor 
requirements  of Ca2+ ions, phospholipids and activated factor V (FVa) for their optimal 
activities (Joseph et al. 1999). We determined the amino acid sequence of trocarin D and its 
precursor using Edman degradation (Joseph et al. 1999) and cDNA sequencing (Reza et al. 
2005a), respectively. Trocarin D and mammalian FXa share significant sequence identity 
(~53-60%) and exhibit identical domain architecture (Joseph et al. 1999; Rao et al. 2003a) 
(Figure 1). Both proteins comprise two chains: a heavy chain, which has a serine proteinase 
with the characteristic catalytic triad (His42, Asp88 and Ser185), and a light chain, which has a 
Gla domain followed by two epidermal-growth factor-like domains (EGF-I and EGF-II). 
These two chains are held together by a single inter-chain disulfide bond (Joseph et al. 1999) 
(Figure 1). The differences between trocarin D and mammalian FXa reside in an insertion in 
the heavy chain, the size of the activation peptide and post-translational modifications. 
Firstly, there is a 12-residue insert in the heavy chain of trocarin D (Reza et al. 2005a). 
However, the functional importance of this insertion is not clear. Secondly, the activation 
peptide of trocarin D precursor is only 27 residues long (Reza et al. 2005a) compared to the 
activation peptides of mammalian FXs which ranges from 48 to 52 residues (Figure 1). 
Lastly, post-translational modifications show that trocarin D is glycosylated, but 
mammalian FXa is not. In addition, trocarin D also contains a O-linked carbohydrate at Ser52 
of the light chain and a N-linked carbohydrate at Asn45 of the heavy chain (Joseph et al. 
1999) (Figure 1). Interestingly, the O-linked carbohydrate moiety has a N-acetylglucosamine 
moiety, which is found commonly in nuclear and cytoplasmic proteins but rarely in secreted 
proteins (Hanover et al. 1987; Holt et al. 1987; Holt and Hart 1986; Snow et al. 1987). The 
www.intechopen.com
 
Gene Duplication 260 
function of glycosylation is hypothesized to protect trocarin D from inactivation by 
proteolysis and confer it with thermal stability (Rao et al. 2003a; Wang et al. 1996). Although 
human FX contains two O-glycosylation and two N-glycosylation moieties (Inoue and 
Morita 1993), all the carbohydrate moieties are exclusively found on the activation peptide, 
which is removed when FX is activated. Therefore, activated mammalian FXa is not 
glycosylated. In contrast, the short activation peptide of trocarin D does not have any 
glycosylation sites. The last difference in post-translational modification is that the Asp63 of 
FX light chain EGF-I domain is β-hydroxylated (McMullen et al. 1983; Stenflo et al. 1987), 
but the corresponding residue in trocarin D is not (Joseph et al. 1999) (Figure 1).  
 
 
Fig. 1. Domain architecture of mammalian FX, and precursors of trocarin D and PCCS. The 
Ys represent Gla residues; open triangles represent the O-linked carbohydrate at Ser52 on 
trocarin D and PCCS; solid triangles represent the N-linked carbohydrate at Asn45 on 
trocarin D and PCCS; the solid diamond represents β-hydroxylation at Asp62 on mammalian 
FXa. 
2.2 Group C prothrombin activators  
The group C snake venom prothrombin activators are also found exclusively in the venoms 
of Australian elapid snakes (Rosing and Tans 1991). Oscutarin from Oxyuranus scutellatus 
venom was the first member of the group C prothrombin activators to be isolated and 
characterized (Owen and Jackson 1973; Speijer et al. 1986; Walker et al. 1980; Welton and 
Burnell 2005). This group of proteins is generally ~300 kDa in size and comprises two 
subunits (~60 and ~220 kDa) (Table 1). The smaller enzymatic subunit is a serine proteinase 
and has characteristics of FXa, whereas the nonenzymatic subunit resembles activated 
mammalian plasma coagulation factor V (FVa). Overall, group C prothrombin activators 
have striking resemblances to and similar co-factor requirements as the mammalian plasma 
coagulant “FXa-FVa” complex  (Filippovich et al. 2005; Masci et al. 1988; Rao and Kini 2002; 
Speijer et al. 1986; Walker et al. 1980) (Table 1).  
www.intechopen.com
 
Duplication of Coagulation Factor Genes and Evolution of Snake Venom Prothrombin Activators 261 
Pseutarin C was purified from P. textilis venom, and it activates prothrombin to thrombin. 
For its optimal activity, pseutarin C requires only Ca2+ ions and phospholipids (Rao and 
Kini 2002). These functional characteristics are similar to that of the mammalian “FXa-FVa” 
complex. As with other group C prothrombin activators, pseutarin C comprises two 
subunits of ~60 kDa and ~220 kDa (Rao and Kini 2002) (Table 1). The smaller subunit, with 
serine proteinase activity, was termed the pseutarin C catalytic subunit (PCCS) and the 
larger subunit, which has no enzymatic activity, was termed the pseutarin C nonenzymatic 
subunit (PCNS) (Rao and Kini 2002). A comparison of the protein quantities in the venom 
and plasma revealed that pseutarin C is expressed ~4,200 times higher in the venom than 
the amount of FV and FX in the plasma (Rao and Kini 2002). We purified pseutarin C and its 
subunits and characterized them both functionally and structurally as representatives of the 
group C prothrombin activators. 
1. Pseutarin C catalytic subunit (PCCS) – Functionally, PCCS is similar to mammalian FXa and 
group D prothrombin activators (Rao and Kini 2002). They have the same co-factor 
requirements, including Ca2+ ions, phospholipids and FVa, for their optimal activity and 
activate prothrombin by cleaving the same two peptide bonds (Arg274-Thr275 and Arg323-
Ile324). The enzymatic activity (Vmax) of PCCS is enhanced by the presence of FVa (Rao and 
Kini 2002). The amino acid sequence of PCCS and its precursor was determined using both 
Edman degradation and cDNA sequencing (Rao et al. 2004; Rao and Kini 2002). Structurally, 
PCCS is also similar to mammalian FXa and group D prothrombin activators (Figure 1). Its 
sequence shows ~42% identity to mammalian FXa and 74-83% identity to group D 
prothrombin activators (Rao et al. 2004). Like mammalian FXa and group D prothrombin 
activators (Rao et al. 2004), the domain architecture of PCCS consists of a light and a heavy 
chain that are linked by a single disulfide bond (Rao et al. 2004). The light chain has a Gla 
domain followed by two EGF-like domains, and the heavy chain contains a serine 
proteinase domain (Figure 1). Despite such functional and structural similarities, the 
differences between PCCS and mammalian FXa reside in the size of the activation peptide 
and post-translational modifications (Rao et al. 2004). Similar to trocarin D precursor, the 
activation peptide of PCCS precursor is 27 residues long and is significantly shorter than 
those of mammalian FXs (Figure 1). Like trocarin D, it has an insertion in its heavy chain. 
Interestingly, the PCCS insert is 13 residues long and is distinctly different from the 12-
residue insert in trocarin D (Rao et al. 2004; Reza et al. 2005b). This strongly indicates that 
the evolution of groups C and D prothrombin activators are independent. Like trocarin D, 
the Ser52 and Asn45 residues of the light and heavy chains of PCCS are O- and N-
glycosylated, respectively (Figure 1). However, as mentioned previously, these two residues 
have no post-translational modifications in mammalian FX/FXa. These functional and 
structural characteristics suggest that PCCS is a homologue of mammalian FXa and group D 
prothrombin activators. 
2. Pseutarin C nonenzymatic subunit (PCNS) – Structurally, PCNS is similar to mammalian FV. 
The amino acid sequence of PCNS and its precursor was determined using Edman 
degradation and cDNA sequencing (Rao et al. 2003b; Rao and Kini 2002). PCNS shares ~50% 
identity with the mammalian FV and has identical domain architecture with mammalian FV 
(Rao et al. 2003b). Both PCNS and mammalian FV have six domains: A1, A2, B, A3, C1 and 
C2 (Figure 2). Domains A and C are functionally important, and these domains are highly 
conserved in PCNS and FVs of other species (Rao et al. 2003b). These structural similarities 
suggest that PCNS is a homologue of mammalian FV (Rao et al. 2003b). 
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Fig. 2. Domain architecture of bovine FV, PCNS precursor and PFV. N-glycosylation sites 
are shown as colored knobs. Black knobs are conserved, while red knobs are found only in 
PCNS and PFV, and blue knobs are found only in PFV. 
Despite being a FV homologue, PCNS shows several differences with FV from other species. 
Firstly, the domain B size of PCNS is significantly smaller (127 residues) than that of fishes 
(fugu: 530 residues and zebrafish: 756 residues) and mammals (murine: 843 residues, 
bovine: 869 residues, and human: 882 residues) (Rao et al. 2003b) (Figure 2). During FV 
activation, domain B is removed by thrombin or FXa by cleavage at three activation sites: 
Arg709, Arg1018 and Arg1545 (bovine FV numbering) (Foster et al. 1983; Nesheim et al. 1979; 
Suzuki et al. 1982) (Figure 3B). Although only two of these sites (Arg709 and Arg1545) are 
conserved in PCNS (Figure 3B), the complete domain B can still be cleaved off during the 
activation of PCNS (Rao et al. 2003b). Thus, the difference in domain B size should not have 
any effect on the function of PCNS. Secondly, PCNS and FV of other species have different 
post-translation modifications. While bovine FV has 29 glycosylation sites, PCNS has only 
11 potential N-glycosylation sites (Rao et al. 2003b) (Figure 2). Mammalian FV is 
phosphorylated at the Ser692 residue, but PCNS is not (Rao et al. 2003b). In addition, there 
are six sulfation sites in human FV that are absent in PCNS (Rao et al. 2003b). This difference 
in post-translation modifications is interesting, as sulfation and phosphorylation are 
important for regulating the activation of human FV by thrombin (Kalafatis et al. 1994; 
Pittman et al. 1994).  
Aside from these differences, it is noted that PCNS possesses certain modifications and 
associations that allow it to function efficiently as a toxin (Bos et al. 2009). Firstly, PCNS has 
evolved a way to evade inactivation by protein C. In the human coagulation system, protein 
C is activated by thrombin in the presence of thrombomodulin, and activated protein C 
(APC) subsequently inactivates FVa in a negative feedback loop (Esmon 2001). This 
inactivation occurs by proteolytic cleavage at three sites on the FVa heavy chain: Arg306, 
Arg506 and Arg662 (Kalafatis et al. 1994; Mann et al. 1997) in bovine FVa (Figure 3B). PCNS is 
able to evade APC inactivation, as it does not have any of the three APC cleavage sites (Rao 
et al. 2003b). Even an alternate less efficient cleavage site at Arg316 (van der Neut et al. 2004b) 
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is not conserved in PCNS (Rao et al. 2003b). Secondly, FVa is inactivated by phosphorylation 
at Ser692 (Kalafatis et al. 1994). This phosphorylation site is not present in PCNS (Rao et al. 
2003b). Lastly, PCNS is shielded from APC inactivation (Nesheim et al. 1982; Rao et al. 
2003b) and is kept activated through its constant and stable association with FXa-like PCCS 
(Rao et al. 2003a; Rao et al. 2004; Thorelli et al. 1998) in the venom. We have shown 
experimentally that pseutarin C is unaffected by APC, while bovine FXa-FVa complex is 
completely inactivated (Bos et al. 2009; Rao et al. 2003b) (Figure 4). Overall, PCNS is a good 
example of how a toxin gene is duplicated from an ancestral gene and undergoes 
modifications to gain unique characteristics that allow it to function efficiently as a toxin. 
 
 
 
 
 
 
 
Fig. 3. Functionally important proteolytic sites in PCNS and FV. (A) Activation sites. 
Thrombin and FXa cleavage sites of PCNS, PFV and bovine FV are shown in blue, green and 
red, respectively. Critical activation sites are conserved in PCNS and PFV. (B) Inactivation 
sites. Activated protein C (APC) cleavage sites of PFV and bovine FV are shown in green 
and red, respectively. In addition to Arg505, PFV has a primitive inactive site at Arg316 shown 
in purple arrow. Inactivation sites are missing in PCNS. 
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Fig. 4. APC resistance assay (Rao et al. 2003b). Varying concentrations of APC were added 
either to pseutarin C (E; 8 nM) or bovine FXa-FVa (F; FXa 42 nM, FVa 2 nM) complex which 
was diluted in 50 mM Tris-HCl buffer (pH 7.5) containing 100 mM NaCl, 5 mM CaCl2, and 
0.5 mg/mL BSA. The reaction mixture was incubated for 30 minutes at room temperature. 
Prothrombin was added to a final concentration of 2.8 µM and thrombin formed was 
assayed using thrombin-specific chromogenic substrate S-2238. Each point represents an 
average of 2 independent experiments each carried out in triplicates.  
3. Parallel prothrombin activator system in Australian elapid snakes 
As described above, groups C and D snake venom prothrombin activators are functional 
and structural homologues of mammalian blood coagulation factors. As snakes are 
vertebrates, their hemostatic system should contain plasma coagulation factors. Thus, 
Australian elapid snakes should possess parallel prothrombin activating systems: one in 
their venom, which is used as an offensive weapon to attack the hemostatic system of the 
prey, and the other in their plasma, which is used for their own hemostatic purpose. We 
examined the presence of plasma coagulation factors in the snake’s hemostatic system and 
determined the relationship between the snake venom and plasma coagulation factors.  
3.1 Trocarin D and FX from Tropidechis carinatus (TrFX) 
Since the liver mainly expresses plasma coagulation factors, the cDNA encoding T. carinatus 
FX (TrFX) was sequenced from liver tissue (Reza et al. 2005a). The deduced amino acid 
sequence of TrFX is similar to mammalian FX (~50%) and trocarin D (~80%) (Figure 5). 
Structurally, TrFX is similar to trocarin D. They both have conserved cysteine residues and 
identical domain architecture. However, there are some differences between TrFX and 
trocarin D. The activation peptide of TrFX is similar to the mammalian FXs and not to that of 
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the venom prothrombin activators (Reza et al. 2005b). It is 57 residues long compared to 27 
residues in trocarin D (Figure 5). In addition, there is no 12-residue insert in the heavy chain 
of TrFX as was observed to be present in the trocarin D precursor (Reza et al. 2005b). These 
differences in amino acid sequences, and the lengths of activation peptides and insertion in 
the heavy chain, suggest that TrFX and trocarin D are encoded by two independent genes. 
Hence, this confirms the presence of a parallel prothrombin activator system. TrFX is more 
similar to trocarin than to mammalian FX in terms of post-translational modifications (Reza 
et al. 2005a). TrFX and trocarin D both have N- and O-glycosylation modifications that are 
not found in mammalian FXs (as described previously). 
 
 
Fig. 5. Alignment of deduced amino acid sequences of FX-like proteins from T. carinatus 
(TrFX and trocarin D) and P. textilis (PCCS, PFX1 and PFX2) snakes. 
Trocarin D and TrFX differ in their physiological roles. Trocarin D plays an offensive role as 
a toxin in the venom that is used for killing prey. Upon envenomation, like other 
prothrombin activators (Masci et al. 1988; Rao et al. 2003a), it induces cyanation and death in 
experimental animals (Joseph et al. 1999) through disseminated intravascular coagulopathy. 
On the other hand, TrFX plays a crucial role in the coagulation cascade and prevents 
excessive blood loss by promoting blood coagulation when there is a vascular injury. 
Trocarin D is an active enzyme and is found in large quantities in the venom. In contrast, 
TrFX is found as a zymogen, which gets activated only when required and is found in much 
smaller concentrations in the plasma. Real-time polymerase chain reaction (RT-PCR) was 
used to determine the amount of expression of these two closely related proteins in the liver 
and venom gland. The results indicate that trocarin D is expressed in the venom gland but 
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TADFANQVLMKQDFGIVSGFGGIFGRGPNSKTLKVLKVPYVDRHTCMLSSNFPITPTMFCAGYDTLPQDACQGDSGGPHITAYRDTHFIT
TADFANEVLMKQDSGIVSGFGRIQFKQPTSNTLKVITVPYVDRHTCMLSSDFRITQNMFCAGYDTLPQDACQGDSGGPHITAYRDTHFIT
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   449Cat
   455
GIISWGEGCAQTGKYGAYTKVSRFILWIKRIMRLKLPSTESSTGRL...
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GIVSSGEGCARNGKYGIYTKLSKFIPWIKRIMRQKLPSTESSTGRL...
GIVSWGEGCARKGRYGIYTKLSKFIPWI.....................
GIISWGEGCARKGKYGVYTKVSKFIPWIKKIMSLK..............
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not in the liver, while TrFX is expressed in the liver but not in the venom gland. Further, the 
expression of trocarin D is ~30 times higher in the venom gland than TrFX in the liver (Reza 
et al. 2007).  Such differential expression patterns of trocarin D and TrFX strongly support 
the distinct physiological roles of these two proteins. 
3.2 PCCS and FX from Pseudonaja textilis (PFX) 
To understand the evolution of group C prothrombin activators, we also determined the 
cDNA sequence of the P. textilis FX (PFX) from the liver. Interestingly, two PFX isoforms 
(PFX1 and PFX2) were detected in the liver, and their cDNA sequences are ~85% similar 
(Reza et al. 2006). The domain architecture and cysteine residues of these two isoforms are 
also conserved compared to group D prothrombin activators. Amino acid sequence 
comparison shows that PFX1 is more similar to TrFX (~94%), while PFX2 is more similar 
PCCS and trocarin D (~90%) (Figure 5). Further, PFX1 has a longer activation peptide, 
similar to plasma FXs, whereas PFX2 has a shorter activation peptide, similar to PCCS and 
trocarin D. Also, PFX2 has a 9-residue insert, which is not present in PFX1. These structural 
differences suggest that PFX1, PFX2 and PCCS are encoded by three independent genes and 
that PFX2 is an evolutionary intermediate between PFX1 and PCCS (Reza et al. 2006) (Figure 
5). This similarly confirms the presence of a parallel prothrombin activator system. The 
expression profiles of PFX1, PFX2 and PCCS were determined in liver and venom gland 
tissues by RT-PCR (Reza et al. 2006). The results show that PFX1 and PFX2 are expressed only 
in the liver, while PCCS is expressed only in the venom gland. PFX1 is also found to be 
expressed ~55,000 times higher than PFX2 in the liver, and PCCS is expressed ~80 times higher 
in the venom gland than is PFX1 in the liver (Reza et al. 2006). In summary, the sequence 
comparisons and expression profiles indicate that PCCS has evolved from PFX1 by gene 
duplication and PFX2 is an intermediary product of this “recruitment” process (Figure 6). 
 
 
Fig. 6. Schematic diagram showing the probable evolutionary path in the recruitment of FX 
protein as toxin in the venom (Reza et al. 2006). 
www.intechopen.com
 
Duplication of Coagulation Factor Genes and Evolution of Snake Venom Prothrombin Activators 267 
3.3 PCNS and FV from Pseudonaja textilis (PFV) 
The cDNA sequence of P. textilis FV (PFV) was determined from its liver (Minh et al. 2005). 
The deduced amino acid sequence of PFV shows similarities to other mammalian and non-
mammalian FVs (~50%) and PCNS (~96%) and shares identical domain architecture (Minh 
et al. 2005). Like the FVs of other species, PFV and PCNS comprise A1, A2, B, A3, C1 and C2 
domains (Figure 3A). Functionally important domains A and C are highly conserved in both 
PFV and PCNS, whereas domain B is the most variable (Minh et al. 2005). The domain B 
(126 residues) of PFV is one residue shorter than that of PCNS (127 residues), and is much 
shorter than that of mammalian and non-mammalian FVs. A more detailed comparison 
shows that all the FXa and thrombin proteolytic cleavage sites (which are important for 
activation of these nonenzymatic proteins) are conserved in PFV and PCNS (Figure 3A). 
However, PFV has an additional FXa proteolytic cleavage site at Arg1765 (Minh et al. 2005; 
Rao et al. 2003b). This cleavage site also exists in mammalian FV but not in FVs of teleosts 
(Minh et al. 2005). This is evolutionarily interesting as this additional cleavage site may be a 
characteristic found only in tetrapod FVs. However, the functional implication of this 
cleavage with regards to procoagulant activity of FV is not yet known. 
As mentioned previously, PCNS has evolved to be resistant to inactivation by activated 
protein C (APC), which is crucial to its function as a toxin. On the other hand, PFV is similar 
to other FV, as it can still be inactivated by APC. PFV can be inactivated by APC by cleavage 
at Arg316, a primitive inactive site (van der Neut et al. 2004a), and at Arg506 (Minh et al. 2005) 
(Figure 3B). The expression profiles of PFV and PCNS in the liver and the venom gland were 
determined using RT-PCR. As with other venom prothrombin activator genes, PCNS is 
expressed only in the venom gland, while PFV is expressed only in the liver. It was found 
that PCNS is expressed ~280 times higher in the venom gland than is PFV in the liver (Minh 
et al. 2005). Thus, PCNS and PFV are have differential expressions (Minh et al. 2005). 
Based on sequence comparisons, we confirmed the presence of parallel prothrombin 
activator systems in Australian elapid snakes and showed for the first time that groups C 
and D prothrombin activators in snake venom and their plasma coagulation factor 
counterparts are closely related. We also proposed that these venom prothrombin activators 
evolved from their plasma coagulation factor counterparts by gene duplication and were 
subsequently modified to function efficiently as toxins. 
4. Phylogenetic relationship between snake venom and plasma prothrombin 
activators 
A phylogenetic tree of the snake venom and plasma prothrombin activators with other 
known FX sequences was constructed to understand their evolutionary relationships using 
zebrafish FX as the out group (Reza et al. 2006; St Pierre et al. 2005). All the reptilian 
sequences form a monophyletic group (Reza et al. 2006) (Figure 7). Within the reptilian 
clade, group C and D prothrombin activators appear as two separate clades on the tree. This 
indicates that, despite their similarities, group C and D prothrombin activators have 
originated independently. Interestingly, the PFX2 sequence is found nested within the 
group C prothrombin activators. This supports the hypothesis that PFX2 is an evolutionary 
intermediate of PCCS from PFX1. Based on the topology of the phylogenetic tree, it is 
suggested that these snake venom prothrombin activators have been “recruited” through  
independent evolutionary events (Reza et al. 2006) (Figure 7). 
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Fig. 7. Phylogenetic relationships of snake venom and plasma prothrombin activators with 
other known FX sequences (Reza et al. 2006). “vPA” is an abbreviation for venom 
prothrombin activators. Arrows indicate the three independent “recruitment” events of 
snake venom prothrombin activators.  
5. Comparison of trocarin D and TrFX genes 
In the previous sections, we have described how the venom prothrombin activators have 
been modified to gain certain characteristics, such as resistance to inactivation, which 
enables them to function better as toxins. However, differential and tissue-specific 
expression of venom prothrombin activators and their plasma coagulation factors is also 
important for their respective physiological roles. The expression of toxins should be venom 
gland-specific and inducible to higher levels. This is so the snake can protect itself against its 
own venom toxins and replenish its venom supply quickly. Conversely, plasma coagulant 
factors are mainly expressed in the liver at constituently low levels so that they can be 
activated to induce blood coagulation during vascular injuries.  
To understand how the venom prothrombin activators are regulated for tissue specificity 
and level of expression, we determined the gene structure of trocarin D and TrFX. Based on 
the cDNA sequences of trocarin D and TrFX, and that of mammalian FX gene, primers were 
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designed, and the gene sequences were determined using genomic DNA PCR and genome 
walking strategies (Reza et al. 2006). The gene organizations of trocarin D and TrFX are 
identical (eight exons and seven introns). The intron sequences were highly similar to each 
other with only differences in the promoter and intron 1 regions (Figure 8). Such similarities 
strongly support our findings that there are two closely related, parallel prothrombin 
activator systems, and that the venom prothrombin activators are “recruited” from plasma 
coagulation factors through gene duplication. The duplicated FX gene was subsequently 
modified and “recruited” for expression in the venom gland as a venom prothrombin 
activator. 
 
 
Fig. 8. Gene organization comparison of trocarin D and TrFX. Exons are shown as numbered 
boxes. The differences in the promoter and intron 1 regions are indicated in yellow 
(insertions in trocarin D gene) and green (deletions in TrFX gene) (Reza et al., 2007). 
5.1 Cis-elements in trocarin D promoter region  
The overlapping promoter regions of trocarin D and TrFX were characterized by 
comparing them against previously characterized human (Hung et al. 2001; Hung and 
High 1996) and murine (Wilberding and Castellino 2000) FX promoter regions (Reza et al. 
2007) (Figure 9). Based on these comparisons, four conserved cis-regulatory elements in 
the trocarin D and TrFX promoter regions were identified (Figure 9): (i) a CCAAT box 
(Hung et al. 2001; Hung and High 1996; Wilberding and Castellino 2000), (ii) a gut-specific 
transcription factor GATA-4 binding site  (Hung et al. 2001), (iii) a liver-specific 
transcription factor HNF-4 (Hung and High 1996), and (iv) multiple Sp1/Sp3 binding 
sites (Hung et al. 2001).  
Comparison of the trocarin D and TrFX promoter regions reveals that trocarin D has a 264 
bp insertion (Figure 8 and 9). This 264 bp is located from -33 to -297 bp upstream of the 
trocarin D start codon (ATG) (Figure 9). This insertion is postulated to play a major role in 
the recruitment of the duplicated TrFX gene by causing it to be exclusively expressed in the 
venom gland as the procoagulant toxin, trocarin D. Hence, it was termed Venom 
Recruitment/Switch Element (VERSE). This segment was characterized for its cis-elements 
and gene-regulatory role using luciferase assays in primary venom gland cells and 
mammalian cell lines (Kwong et al. 2009). The VERSE promoter was found to be responsible 
for the elevation of expression levels, but not tissue-specific expression, of trocarin D. In 
terms of cis-element characterization, besides confirming the presence of two TATA-boxes, 
one GATA box and one Y-box, three novel cis-elements were also identified (Figure 9). 
Functionally, it is found that both TATA boxes (TLB2 and TLB3) are functional. However, 
TLB2 is the primary TATA box which initiates and directs transcription start site (Kwong et 
al. 2009) (Figure 9).  
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Fig. 9. Comparison of promoter regions in mammalian and T. carinatus prothrombin 
activator genes (Reza et al., 2007). 
5.2 Comparison of trocarin D and TrFX first introns 
The intron 1 size of trocarin D is 7911 bp, while that of TrFX is 5293 bp. The difference in 
size is explained by three insertions and two deletions in the trocarin D intron 1 region 
(Reza et al. 2007) (Figure 10). Bioinformatics analysis of these insertion/deletion segments 
reveals that they are novel. The three insertion segments within intron 1 of trocarin D 
region are 214 bp, 1975 bp and 2174 bp in size with respective positions at 128 bp, 914 bp 
and 3300 bp on the trocarin D gene (Figure 10). Upon closer analysis of the insertion 
segment sequences, it is observed that the first insert within intron 1 of trocarin D is 
almost an exact repeat (96.33% identity) of the intron 1 segment spanning from 3082 bp to 
3299 bp. The other two inserts seem to be inverted repeats of each other (~71% identity). 
The third insert shows potential of being a Scaffold/Matrix Attachment Region (S/MAR) 
due to: (i) a high AT content (Cockerill and Garrard 1986; Liebich et al. 2002; Zhou and 
Liu 2001), (ii) a topoisomerase II (Boulikas 1993), (iii) a S/MAR consensus motif (van 
Drunen et al. 1997), (iv) a significant over-representation of characteristic hexanucleotides 
(Liebich et al. 2002), and (v) an ATTA motif and an AT-rich region with H-box (Will et al. 
1998). The two deletion segments within intron 1 of trocarin D are 255 bp and 1406 bp in 
size with respective positions at 2610 bp and 3770 bp on the TrFX gene (Reza et al. 2007) 
(Figure 10). As the VERSE promoter of trocarin D does not regulate tissue-specific 
expression (Kwong et al. 2009), it is postulated that these insertions and deletions in the 
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intron 1 of trocarin D could contain cis-elements that are responsible for the venom gland-
specific expression of trocarin D. In summary, the characterization of the VERSE 
promoter and intron 1 regions of trocarin D has increased our understanding regarding 
gene regulation of venom prothrombin activators. 
 
 
 
Fig. 10. Comparison of intron 1 regions in TrFX and trocarin D genes (Reza et al., 2007). 
6. Gene duplication in snake venom toxin diversification 
Besides “recruitment”, gene duplication also plays an important role in the diversification of 
venom toxins. This diversification is essential for the development of novel toxins. This 
diversification through gene duplication is evident from the many toxin isoforms present in 
the snake venom. Interestingly, each isoform varies in its function and gene regulation.  
Gene duplication has also led to neofunctionalization of venom toxins, which has led to the 
new families of snake venom toxins (St Pierre et al. 2008) and addition of new members 
within these families (Fry et al. 2003; Landan et al. 1991b; Lynch 2007; Moura-da-Silva et al. 
1996). The three-finger toxin (3FTx) multigene family is a good example of 
neofunctionalization by gene duplication (Fry et al. 2003). Structurally, all the members of 
this family have very well-conserved cysteine residues and share a common structure of 
three beta-stranded loops extending from a central core. However, they exhibit a wide 
variety of pharmacological effects. For example, acetylcholinesterase inhibition (fasciculin 
from Dendroaspis angusticeps venom), neurotoxicity (┙-bungarotoxin from Bungarus 
multicinctus venom), cardiotoxicity (┚ cardiotoxin from Ophiophagus hannah venom), and 
many others (for details, see (Kini and Doley 2010)). Neofunctionalization occurs when a 
toxin gene undergoes gene duplication and the duplicated gene is mutated within the 
functional sites, which often results in new ligand-binding specificities (Kini 2002).  
Besides neofunctionalization, changes in gene regulation are also the outcomes of gene 
duplication. This can be seen in two isoforms present in the venom of Naja sputatrix: 
cardiotoxin and ┙-neurotoxin (Ma et al. 2001). Besides varying in function, these two 
isoforms have different expression levels in the venom gland. Cardiotoxin constitutes 60% 
of the venom while the ┙-neurotoxin makes up only 3% of the venom. Gene duplication is 
evident from the gene comparison whereby the structures and amino acid sequence of these 
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two toxins are very well-conserved (Ma et al. 2002). The main difference lies in the promoter 
segment, where it was found that the ┙-neurotoxin promoter contains a stronger silencer 
element, which is responsible for significantly reducing its expression level in the venom 
(Ma et al. 2001; Ma et al. 2002). 
In the case of venom prothrombin activators, we have shown that they have been 
“recruited” from the gene of an ancestral plasma prothrombin activator protein through 
gene duplication. The duplicated gene underwent modifications in its regulatory and 
coding regions to gain toxin characteristics. VERSE segments were inserted in the promoter 
regions of trocarin D and PCCS and are responsible for their elevated level of expression. 
Insertion/deletion segments in their intron 1 regions are postulated to be responsible for 
venom-gland specific expression. Modifications in the gene-coding regions enable 
prothrombin activators to function better as toxin by gaining certain characteristics such as 
resistance to inactivation. 
7. Conclusion 
Gene duplication has played a major role in the development of snake venom toxins. Our 
findings on venom prothrombin activators and blood coagulation factors have captured 
the first molecular evidence of gene duplication. The characterization of the differences in 
their genes, i.e. VERSE segment and intron 1 of trocarin D, has increased our 
understanding of gene regulation of snake venom toxins. It is shown that the VERSE 
segment is responsible for the elevation of gene expression and that the intron 1 is 
probably responsible venom gland-specific expression (unpublished observations). We 
identified three novel cis-elements in the VERSE segment, and these play important roles 
in gene regulation. It would be interesting to further characterize them and their trans-
factor partners to determine how various trans-factors interact with each other to regulate 
gene expression. The answers to some of these questions will increase our overall 
understanding of gene regulation.  
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